New Research Article on ENT Involvement in EGPA

Corisande Baldwin, Nikolaus Ernst Wolter, Christian Pagnoux Research

For full text of this article please access the following link:

Following in the abstract from the research article. Dr. Pagnoux serves on the Medical Advisory Board of the CSSA.


Corisande Baldwin1, Nikolaus Ernst Wolter2 and Christian Pagnoux1*

1Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; 2Department of Otolaryngology – Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada


Eosinophilic granulomatosis with polyangiitis (EGPA) is the rarest of the anti-neutrophil cytoplasm antibody (ANCA)-associated small-vessel vasculitides. In Europe, its prevalence ranges from 10 to 15/million and annual incidence from 0.9 to 1.2/million. EGPA affects men and woman equally, with a mean age of 50 years at diagnosis. The most characteristic features include late-onset asthma, pulmonary infiltrates, mono- or polyneuropathy, and peripheral and extravascular eosinophils. Ear, nose, and throat (ENT) manifestations are particularly frequent, occurring in 30–80% of patients and most often early in the disease process. ENT features include allergic rhinitis, chronic sinusitis and polyposis, lacrimal and salivary gland involvement, otitis media and, rarely, cranial nerve involvement. The diagnosis of EGPA may be relatively straightforward in the 30–40% of ANCA-positive patients and in those with biopsies demonstrating vasculitis, but it can be more challenging, or even debatable, in ANCA-negative patients who do not present clear evidence of vasculitis. Because EGPA is a multisystem disease, it requires a multidisciplinary approach for diagnosis and management, including by an otolaryngologist.

Go back